Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,748,000 | 3,104,000 | 1,325,000 | 13,402,000 | 4,173,000 |
| Depreciation Amortization | 2,324,000 | 1,533,000 | 756,000 | 3,218,000 | 2,411,000 |
| Accounts receivable | -874,000 | -672,000 | -262,000 | -691,000 | -533,000 |
| Other Working Capital | -913,000 | -924,000 | -517,000 | -9,217,000 | -826,000 |
| Other Operating Activity | 966,000 | 423,000 | 115,000 | 1,846,000 | 465,000 |
| Operating Cash Flow | $6,251,000 | $3,464,000 | $1,417,000 | $8,558,000 | $5,690,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 46,000 | -44,000 | 8,000 | N/A | 9,000 |
| PPE Investments | -1,482,000 | -986,000 | -484,000 | -2,207,000 | -1,487,000 |
| Net Acquisitions | -85,000 | -30,000 | N/A | 1,000 | 1,000 |
| Purchase Of Investment | N/A | N/A | N/A | -169,000 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 28,000 | N/A |
| Other Investing Activity | 12,000 | 8,000 | 6,000 | 9,000 | 5,000 |
| Investing Cash Flow | $-1,509,000 | $-1,052,000 | $-470,000 | $-2,338,000 | $-1,472,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -44,000 | -52,000 | -36,000 | -100,000 | -126,000 |
| Debt Issued | 3,000 | 3,000 | 1,000 | 223,000 | 222,000 |
| Debt Repayment | -1,503,000 | -1,002,000 | -1,001,000 | -660,000 | -20,000 |
| Common Stock Issued | 391,000 | 322,000 | 287,000 | 264,000 | 239,000 |
| Common Stock Repurchased | -591,000 | -286,000 | -280,000 | -1,295,000 | -980,000 |
| Dividend Paid | -3,086,000 | -2,055,000 | -1,026,000 | -3,836,000 | -2,878,000 |
| Other Financing Activity | -82,000 | -82,000 | 0 | 0 | 0 |
| Financing Cash Flow | $-4,912,000 | $-3,152,000 | $-2,055,000 | $-5,404,000 | $-3,543,000 |
| Exchange Rate Effect | 65,000 | 75,000 | 24,000 | -96,000 | -13,000 |
| Beginning Cash Position | 7,616,000 | 7,616,000 | 7,616,000 | 6,896,000 | 6,896,000 |
| End Cash Position | 7,511,000 | 6,951,000 | 6,532,000 | 7,616,000 | 7,558,000 |
| Net Cash Flow | $-105,000 | $-665,000 | $-1,084,000 | $720,000 | $662,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,251,000 | 3,464,000 | 1,417,000 | 8,558,000 | 5,690,000 |
| Capital Expenditure | -1,482,000 | -986,000 | -484,000 | -2,207,000 | -1,487,000 |
| Free Cash Flow | 4,769,000 | 2,478,000 | 933,000 | 6,351,000 | 4,203,000 |